Based on the results of the phase III ALCANZA clinical trial, in November 2017, the FDA granted regular approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous ALCL or CD30-expressing MF who have received prior systemic therapy. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.